1. Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM)
- Author
-
Diyar Z. Akkaynak, Yeşim Oymak, Gonul Aydogan, Tuğba Gürleyen Eren, Gülsün Karasu, Bahattin Tunç, Fatma Gumruk, Selma Unal, Umran Caliskan, Turkan Patiroglu, Adalet Meral Güneş, Zafer Salcioglu, Ahmet Koç, Yusuf Ziya Aral, Yasemin Isik Balci, Mehmet Akin, Aylin Canbolat Ayhan, Vedat Uygun, Osman Alphan Küpesiz, Gönül Oktay, Canan Vergin, Betül Biner, İlgen Şaşmaz, Mehmet Ertem, Hilmi Apak, Emine Türkkan, Yıldız Yildirmak, Cetin Timur, Elif Güler Kazanci, Gülersu Irken, Ülker Koçak, Murat Söker, Erdal Kurtoğlu, Mehmet Akif Yesilipek, Bülent Antmen, Zeynep Karakas, and Çukurova Üniversitesi
- Subjects
Male ,thalassemia ,drug safety ,creatinine blood level ,Turkey ,Thalassemia ,Gastroenterology ,preschool child ,Cohort Studies ,chemistry.chemical_compound ,0302 clinical medicine ,iron ,Prospective cohort study ,Child ,iron chelation ,chelation therapy ,adult ,creatinine ,kidney tubule disorder ,clinical trial ,Hematology ,General Medicine ,biological marker ,cohort analysis ,Sickle cell anemia ,Hemoglobinopathy ,female ,Treatment Outcome ,priority journal ,030220 oncology & carcinogenesis ,monotherapy ,Child, Preschool ,Cohort ,Female ,liver enzyme ,deferasirox ,medicine.drug ,medicine.medical_specialty ,Iron Overload ,erythrocyte transfusion ,side effect ,Adolescent ,Iron ,complication ,Anemia, Sickle Cell ,protein urine level ,blood transfusion ,Iron Chelating Agents ,Anemia, Sickle Cell/*complications/therapy ,Biomarkers ,Blood Transfusion ,Deferasirox/administration & dosage/adverse effects/*therapeutic use ,Ferritins/blood/metabolism ,Humans ,Iron/blood/metabolism ,Iron Chelating Agents/administration & dosage/adverse effects/*therapeutic use ,Iron Overload/*drug therapy/*etiology/metabolism ,Thalassemia/*complications/therapy ,Article ,enzyme blood level ,03 medical and health sciences ,sickle cell anemia ,blood ,turkey (bird) ,Internal medicine ,medicine ,hemoglobinopathy ,follow up ,human ,iron overload ,drug dose reduction ,Adverse effect ,transfusion ,Creatinine ,business.industry ,Deferasirox ,ferritin ,abdominal pain ,iron chelating agent ,medicine.disease ,school child ,major clinical study ,drug efficacy ,ferritin blood level ,pediatric ,multicenter study ,chemistry ,Ferritins ,observational study ,proteinuria ,business ,metabolism ,030215 immunology - Abstract
PubMedID: 30300449 Objectives: To evaluate the long-term efficacy and safety of deferasirox therapy in a large observational cohort of children with transfusion-dependent thalassemia (TDT) and sickle cell anemia (SCA) in Turkey. Methods: This was a multicenter, prospective cohort study including TDT and SCA patients aged 2-18 years with iron overload (?100 mL/kg of pRBC or a serum ferritin [SF] level >1000 µg/L) receiving deferasirox. Patients were followed for up to 3 years according to standard practice. Results: A total of 439 patients were evaluated (415 [94.5%] TDT, 143 [32.6%] between 2 and 6 years). Serum ferritin levels consistently and significantly decreased across 3 years of deferasirox therapy from a median of 1775.5 to 1250.5 µg/L (P
- Published
- 2019